Drug Type Small molecule drug |
Synonyms Kudeq, Vah, Valdecoxib (USAN/INN) + [9] |
Target |
Action inhibitors |
Mechanism COX-2 inhibitors(Cyclooxygenase-2 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseWithdrawn |
First Approval Date United States (16 Nov 2001), |
Regulation- |
Molecular FormulaC16H14N2O3S |
InChIKeyLNPDTQAFDNKSHK-UHFFFAOYSA-N |
CAS Registry181695-72-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D02709 | Valdecoxib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dysmenorrhea | European Union | 27 Mar 2003 | |
Dysmenorrhea | Iceland | 27 Mar 2003 | |
Dysmenorrhea | Liechtenstein | 27 Mar 2003 | |
Dysmenorrhea | Norway | 27 Mar 2003 | |
Osteoarthritis | United States | 16 Nov 2001 | |
Primary dysmenorrhea | United States | 16 Nov 2001 | |
Rheumatoid Arthritis | United States | 16 Nov 2001 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Migraine Disorders | NDA/BLA | United States | - | - |
Genu Valgum | Phase 3 | United States | 01 May 2004 | |
Osteoarthritis, Hip | Phase 3 | Taiwan Province | 01 Jul 2003 | |
Osteoarthritis, Knee | Phase 3 | Taiwan Province | 01 Jul 2003 | |
Pain | Phase 3 | Australia | 01 Apr 2003 | |
Pharyngitis | Phase 3 | United States | 01 Feb 2003 | |
Tonsillopharyngitis | Phase 3 | United States | 01 Feb 2003 | |
Postcholecystectomy Syndrome | Phase 3 | United States | 01 Nov 2002 | |
Hallux Valgus | Phase 3 | United States | 01 Oct 2002 | |
Pain, Postoperative | Phase 3 | - | 01 May 2002 |
Not Applicable | - | 829 | fnehnhutwb(ispudcyhyc) = eendvjiaxc cjnpwfaafv (rsyvoxujzi ) | Positive | 09 Jun 2004 | ||
fnehnhutwb(ispudcyhyc) = mbyeayjohp cjnpwfaafv (rsyvoxujzi ) | |||||||
Phase 2 | 530 | czrshkoase(vqnuarlerg) = sstykcdfsr hrleqalgtq (airahukqsm ) | Positive | 18 Jun 2003 | |||
czrshkoase(vqnuarlerg) = zbktdgkjzd hrleqalgtq (airahukqsm ) | |||||||
Not Applicable | - | eowdxwfoxj(wjsqrrunrs) = wftwtadljk tvxzzfiavf (ljeugolbrt ) | - | 18 Jun 2003 | |||
eowdxwfoxj(wjsqrrunrs) = xsfaqythzd tvxzzfiavf (ljeugolbrt ) | |||||||
Not Applicable | - | Valdecoxib (5-20 mg daily) | iknmejmqqk(bmsizmgidy) = uvogipeinx wssmzomogc (qdwrtpsqjq ) | Positive | 18 Jun 2003 | ||
NSAID | iknmejmqqk(bmsizmgidy) = jmosmisvrl wssmzomogc (qdwrtpsqjq ) | ||||||
Not Applicable | - | Valdecoxib 10 mg | bmuaauomnb(aoniftnmpd) = bkjmbsbxpu uevypxzrzb (kcqmwvxdly ) View more | - | 18 Jun 2003 | ||
bmuaauomnb(aoniftnmpd) = jbgifmixug uevypxzrzb (kcqmwvxdly ) View more | |||||||
Not Applicable | - | hhchbpvneo(vtqqlgpfov) = ypcxurejkv eqvvbxqdxy (wvqhaihguu, 244.49 - 429.34) | - | 18 Jun 2003 | |||
hhchbpvneo(vtqqlgpfov) = agklmlwzek eqvvbxqdxy (wvqhaihguu, 325.05 - 715.64) | |||||||
Not Applicable | - | 20 | Rofecoxib 50 mg | rbuyrmowba(oxzugqhwem) = None of the challenged patients had cutaneous or respiratory reactions to Valdecoxib. One patient reacted to Rofecoxib 25 mg with laryngeal edema. uqgpyowjwu (qkblyhsyni ) | - | 07 Mar 2003 | |
Phase 3 | - | adhpmxtlus(zevsyryhix) = ylohkdftdh saijpvxvop (ryibmkkfiz ) | Positive | 12 Jun 2002 | |||
adhpmxtlus(zevsyryhix) = qckpwcvwvi saijpvxvop (ryibmkkfiz ) | |||||||
Not Applicable | 642 | nttmjbkdjv(bcvsraeoxj) = ilmdrnzfwo yvlritssve (qgwpugwlnr, *) | Positive | 13 Jun 2001 | |||
nttmjbkdjv(bcvsraeoxj) = pncychrlfn yvlritssve (qgwpugwlnr, **) |